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Background: The objective of this study is to investigate the feasibility and the additional interest of a parametric
imaging (PI) method to monitor the early tumour metabolic response in a prospective series of oesophageal cancer
patients who underwent positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET/CT) before and
during curative-intent chemo-radiotherapy.
Methods: Fifty-seven patients with squamous cell carcinoma (SCC) of the oesophagus prospectively underwent
FDG-PET/CT before chemo-radiotherapy (CRT) (PET1) and at 21 ± 3 days after the beginning of CRT (PET2). The
outcome was assessed at 3 months and 1 year after the completion of CRT (clinical examination, CT scan or
FDG-PET/CT, biopsy). For each patient, PET1 and PET2 were registered using CT images. The 2 PET image sets were
subtracted, so the voxels with significant changes in FDG uptake were identified. A model-based analysis of this
graph was used to identify the tumour voxels in which significant changes occurred between the two scans and
yielded indices characterising these changes (green and red clusters). Quantitative parameters were compared with
clinical outcome at 3 months and at 1 year.
Results: The baseline tumour FDG uptake decreased significantly at PET2 (p < 0.0001). The tumour volume
significantly decreased between PET1 and PET2 (p < 0.02). The initial functional volume of the lesion (TV1) was
significantly lower (p < 0.02) in patients in clinical response (CR) at 3 months and 1 year. The volume of the lesion
during the treatment (TV2) was significantly lower in patients identified as in CR at 3 months (p < 0.03), but did not
predict the outcome at 1 year. Multivariate analyses of outcome at 3 months showed that the risk of failure/death
increased with younger age (p = 0.001), larger metabolic volume on PET1 (p = 0.009) and larger volume with
decreased FDG uptake (p = 0.047). As for outcome at 1 year, the risk of failure/death increased with younger age
(p = 0.006), nodal involvement (p = 0.08) and larger volumes with increased uptake (p = 0.03).
Conclusion: A parametric method to assess tumour response on serial FDG-PET performed during
chemo-radiotherapy was evaluated. Early metabolic changes, i.e. variations in FDG uptake, provided additional
prognostic information in multivariate analyses ClinicalTrials.gov NCT 00934505.
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Parametric imagingBackground
Positron emission tomography with fluoro-2-deoxy-D-
glucose (FDG-PET/CT) is commonly used in the initial
staging and post-treatment follow-up of many cancer pa-
tients [1,2]. Since metabolic changes under treatment are
likely to precede anatomic alterations [3-5], FDG-PET/CT
is actively investigated as a way to assess tumour response
to chemotherapy (CT) and radiotherapy (RT) in lymph-
omas [6,7], non-small cell lung [8-10], head and neck [11],
and colorectal and breast cancers [12].
Oesophageal cancer is the third most frequent gastro-
intestinal cancer, with a poor prognosis and high mortal-
ity rates (5-year survival rates around 4% to 10% [13]).
In clinical practice, FDG-PET has a well-established role
in the diagnosis and staging of oesophageal cancer [14].
Comparisons of FDG uptake before and after treatment
reported a better outcome in patients with complete meta-
bolic response [15,16]. Definitive chemo-radiotherapy
(CRT) has become the first-line therapeutic standard in
patients with locally advanced tumours [17,18]. At the
time of diagnosis, less than 50% of these patients have
potentially operable tumours [19]. The early identification
(e.g. around 25 to 30 Gy) of the tumours that do not
respond to CRT would suggest to go for surgery and avoid
full-dose CRT toxicity. Due to the heterogeneity of the
published series [20], FDG-PET/CT cannot be yet recom-
mended in routine practice to guide the initial treatment
of patients with oesophageal cancer [21], particularly in
those with squamous cell carcinoma [22].
The guidelines for tumour response assessment [23] in-
clude several indices quantifying FDG uptake (standard
uptake value (SUV)max, SUVmean, SUVpeak and total le-
sion glycolysis (TLG)) or metabolic volume (tumour lon-
gitudinal length (TL) and tumour volume (TV)) [24,25].
These indices are calculated on a regional basis, i.e. repre-
sent index values measured over the whole tumour.
Complex changes in tumour uptake/volume, namely het-
erogeneity in tumour response, can therefore be over-
looked. An automatic method using parametric imaging
(PI) has been proposed to quantify FDG uptake variations
in metastatic colorectal cancers [26]. The main interest of
this approach is its ability to describe heterogeneous
tumour response at the voxel level.
In a previous analysis of 57 patients with oesophageal
squamous cell carcinoma (SCC) and recruited in a pro-
spective study [27], we showed that the parameters de-
rived from baseline FDG-PET were good predictors ofoutcome after CRT: larger tumour volume and higher
SUVmax/TLG were associated to poor outcome at
3 months. Higher SUVmax values were also predictors
of poor outcome at 1 year. FDG-PET performed during
CRT at day 21 appeared to be of lower clinical relevance.
We present a reanalysis of the same series, where the PI
method was used to investigate the predictive value of
the metabolic variations observed between FDG-PET/
CT performed before and during curative-intent CRT.
Our goal was to demonstrate that the PI method was ap-
plicable to oesophageal SCC treated with concomitant
radiotherapy and chemotherapy (and not limited to
colorectal cancers after chemotherapy as initially de-
scribed) and that it would provide additional information
to conventional clinical and FDG-PET/CT data.
Methods
Study design
The design of the study (RTEP3, NCT 00934505, http://
www.clinicaltrials.gov/) has been previously described (see
details in [27]). Briefly, patients with histological proof of
oesophageal SCC and candidate to curative-intent CRT
[28] were prospectively included after signing a consent
form. The target sample size was 100 patients. Slow re-
cruitment led us to close the study after the inclusion of
57 patients, an intermediary analysis showing that statis-
tical significance would not be reached with the planned
sample size.
Initial staging included oesophagoscopy with biopsies,
chest and abdominal computed tomography (CT scan)
and endoscopic ultrasound. Each patient underwent
FDG-PET at baseline within 15 days before CRT (PET1)
and at day 21 (± 3 days) of CRT (PET2). Tumour re-
sponse was assessed at 3 months and 1 year after CRT
with clinical investigation, CT or FDG-PET/CT, and
oesophagoscopy with biopsies (if possible).
FDG-PET imaging
The images were acquired with the arms positioned over
the head and with free breathing. Six to eight bed positions
per patient were acquired from the head to the upper third
of the thighs. The FDG-PET scanners used were as follows:
Biograph Sensation 16 (Siemens, Erlangen, Germany),
Gemini (Philips, Best, The Netherlands) and Discovery LS
(General Electric Medical Systems, Milwaukie, OR, USA).
A specific phantom [29] was developed and used to com-
pare and follow the quality control of the PET devices in
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scans were performed using the same machine and under
the same operational conditions, i.e. the patients fasted
overnight or for at least 6 h, blood glucose levels were mea-
sured before each FDG-PET/CT. A total of 4.5 MBq/kg
was administered intravenously after a rest period of at least
20 min. The acquisitions had to start at 60 ± 10 min post-
injection. The same post-injection delay (±5 min) was
mandatory for PET2 during CRT. Reconstruction of the
PET images was performed using ordered subset expect-
ation maximisation (OSEM). The PET images were cor-
rected for random coincidences, scatter and attenuation
using the CT scan data.
FDG-PET/CT analysis
All of the FDG-PET/CT images were collected in Rouen
to insure homogeneous analyses.
Quantitative analysis
The FDG-PET/CT images were analysed on a Leonardo®
clinical workstation with TrueD® software (Siemens
Medical Solutions, Hoffman Estates, Knoxville, TN,
USA). For each patient, an experienced nuclear phys-
ician selected regions of interest (ROIs) in the most in-
tense areas of FDG accumulation in the primary tumour
on PET1. Any increased FDG uptake was compared with
the anatomical findings from the CT scan. The presence
of possible oesophagitis was defined by a moderate FDG
uptake on the PET2, with a disappearance of uptake at
3-month and/or 1-year follow-up and the absence of re-
currence at 3 months and 1 year. The tumour volume
(cm3) was manually determined by a single nuclear
medicine physician (OP) using a percentage of the SUV-
max (TV1 for PET1 and TV2 for PET2). The reproduci-
bility and the advantage of the visual determination of
the functional volume by physician have been previously
shown and discussed [27]. The maximum SUV was de-
fined as the highest-activity voxel value (SUVmax1 for
PET1 and SUVmax2 for PET2). The mean SUV in TV
was defined as the mean tumour activity concentration
(SUVmean1 for PET1 and SUVmean2 for PET2). The
percentage (Δ%) of change between PET1 and PET2 was
calculated as (PET1-PET2)/PET1 for SUVmax (Δ%SUV-
max), SUVmean (Δ%SUVmean) and TV (Δ%TV).
Parametric imaging method
The salient feature of the PI analysis is to assess the
changes in metabolic activity at the voxel level in order
to underline heterogeneities in tumour response [26].
The FDG-PET/CT images were transferred on a Dosi-
soft workstation (v 1.4, Oncoplanet, DosiSoft, Cachan,
France). For each patient, a large cubic VOI was selected
in the most intense area of FDG accumulation in the
primary tumour and lymph nodes on the baseline(PET1) and mid-treatment PET images (PET2), by an ex-
perienced nuclear physician. PET1 and PET2 were co-
registered using a rigid method, under visual control
and combined with an affine method when necessary.
The registration was restricted to the thorax to limit the
uncertainties on the oesophagus position. PET1 and
PET2 datasets were subtracted, yielding a 3D image of
the VOI, with the signal in each voxel i being propor-
tional to the difference in SUV: DIFF(i) = (SUV2(i) −
SUV1(i)). Then, the voxels of DIFF were classified into
four classes according to the voxel values in both the
PET1 and DIFF datasets as follows:
Cl1: high SUV on PET1 and decreased SUV on PET2
Cl2: SUV increased between PET1 and PET2
Cl3: low SUV on PET1 with no substantial SUV
changes at PET2 (i.e. background, etc.)
Cl4: voxels in which physiologic changes are not re-
lated to the tumour masses (i.e. voxels with a low SUV
on PET1) (i.e. heart, lung disease, etc.).
Voxel classification was performed using a stochastic
expectation maximisation algorithm, assuming a Gaussian
mixture model (GMM) for the distribution of voxel values
[26]. A parametric dataset was created from DIFF by set-
ting the signal in voxels belonging to Cl3 and Cl4 to zero.
For visualisation purpose, the voxels belonging to Cl1 (de-
creased uptake) were coded on a green colour scale, and
the voxels belonging to Cl2 (increased uptake) were coded
on a red colour scale. By definition, no stable voxel activity
could be observed in the parametric volume. At the end
of the process, the PI consists of one or several clusters of
voxels either red (r) or green (g). The green clusters repre-
sent the part(s) of the tumours with decreased in SUV,
while the red clusters represent the part(s) with increase
in SUV between PET1 and PET2. The cluster volume (Vr
or Vg in cm
3) was calculated for each cluster.
Statistical analysis
The primary endpoint was disease-free survival at
3 months and 1 year after treatment, with local/regional/
distant relapse or death being considered as events.
Complete response (CR) to CRT was defined as no re-
sidual tumour detected at endoscopy (negative biopsies)
and without regional or distant disease on CT or FDG-
PET/CT.
All statistical analyses were performed with NCSS soft-
ware (version 07.1.18, Kaysville, UT, USA). As for uni-
variate analyses, categorical variables were compared
using chi-squared tests, with Yates' correction for small
samples. Quantitative variables were compared using t
tests after natural logarithm transformation to obtain
Gaussian distributions. Multivariate analyses were per-
formed using stepwise logistic regression. A threshold of
p ≤ 0.05 was considered as statistically significant (bilat-
eral tests).
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Fifty-seven patients were prospectively included. Patients
8, 16, 25, 31 and 40 were secondarily excluded because
of disease progression at the time of diagnosis. Patient
14 died during RCT. In comparison with the initial study
[27], and for technical reasons related to the impossibil-
ity to use CT images in the co-registration method in
the software (non joined slices), the PET1 of patients 42
and 45 and the PET2 of patients 6, 27 and 50 were not
available. As a result, 46 patients were fully evaluable.
Table 1 shows the characteristics of the 46 evaluable
patients. Five patients (11%) had cancer extending to
more than one anatomical third of the oesophagus.
Twenty-nine (63%) and 22 (48%) patients were alive
without disease at 3 months and at 1 year, respectively.
At least one green cluster was observed in all the 46
evaluable patients, demonstrating some SUV decrease
between the two PET examinations. Eight patients had
two green clusters, none had three green clusters, one
had four green clusters, and two had five green clusters.
Fifteen patients had at least one red cluster, nine had
two red clusters, two had three red clusters, one had
four red clusters, and one had five red clusters. The
presence of both green and red clusters in the same pa-
tient illustrates the spatially heterogeneous evolution of
lesions' uptake. An example is shown in Figure 1.
The patients who died or those without complete re-
mission at 3 months (Table 2) were more likely to haveTable 1 Patients' characteristics
Characteristics Evaluable patients (46)
Sex: F/M (%) 4 (9)/42 (91)
Age (years), mean (range) 62 (39 to 82)









cN + a 16 (35)




Upper + middle 3 (7)
Middle + lower 2 (4)
aEnlarged lymph nodes on CT scan or EUS or metabolic lymph nodes
on FDG-PET/CT.T4 cancer, tumour extending to more than one third of
the oesophagus, nodal involvement, larger metabolic vol-
umes on PET1 and PET2, and larger green (regression)
or red (progression) volumes on FDG-PET/CT paramet-
ric analysis. At 1 year (Table 3), the patients who died or
those without complete remission were younger, had lar-
ger tumours (more than one third of the oesophagus
and larger metabolic volume on PET1) with more fre-
quent nodal involvement and had larger red volumes
(progression).
Multivariate analyses (Table 4) of outcome at 3 months
showed that the risk of failure/death increased with
younger age (p = 0.001), larger metabolic volume on
PET1 (p = 0.009) and larger green volume (p = 0.047). As
for outcome at 1 year, the risk of failure/death increased
with younger age (p = 0.006), nodal involvement (p =
0.08) and larger red volumes (p = 0.03).
Discussion
In this prospective, multicentre study, an automated
parametric method [26] was successfully used to investi-
gate the prognostic value of variations in FDG uptake
during curative-intent RCT in oesophageal squamous
cell carcinoma. The co-registration of sequential PET
examinations allows a voxel-based analysis, as a way to
investigate spatial variability in tumour response to
treatment. In multivariate analyses, a larger volume of
red voxels, i.e. with increased uptake between baseline
PET and PET performed at day 21, was significantly as-
sociated with a greater probability of treatment failure/
death at 1 year.
Our results were obtained in a homogeneous popula-
tion of patients with oesophageal squamous cell carcin-
oma. Oesophageal squamous cell carcinoma is very
sensitive to CRT [30]. During CRT, SUVmax, SUVmean
and TV decreased sharply (Table 2). The SUV value de-
pends on several parameters: delay between injection
and acquisition [31], noise level, spatial resolution in the
reconstructed images, and region selected to estimate
the SUV [32]. SUV measurements have been shown to
vary between centres [33]; thus, multicentre studies
require rigorous standardisation of the FDG-PET proce-
dures [34]. In the present study, all of the paired FDG-
PET/CTs for a given patient were performed in the same
department, avoiding inter-centre variability. The cross-
calibration of the participating centres was assessed in a
previous clinical study [35]. The performance and qual-
ity control of the PET/CT devices were monitored by
using a specific phantom developed by our group [29],
and the post-injection delay was kept constant to facili-
tate inter-patient and inter-centre comparison. All quan-
titative analyses were performed in Rouen on the same
workstation by one nuclear medicine physician. We re-
lied on an experienced nuclear medicine physician to
Figure 1 Parametric analysis of the variations in FDG uptake before and during treatment. Left panel: before treatment (TEP1), right panel:
at day 21 during treatment (TEP2), middle panel: co-registration of TEP1 and TEP2. The green voxels are those in which FDG uptake has decreased
between TEP1 and TEP2; the red voxels are those in which FDG uptake has increased. Voxels in which FDG uptake remained stable do not appear.
(A) All voxels are green, indicating homogeneous decrease in FDG uptake (patient was in CR at 1, but small Vg of 6 cm
3). (B) An example of
spatially heterogeneous response, with green and red voxels appearing in the same tumour (patient with recurrence at 1 year). (C) A 3D
visualisation of the PI imaging.
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FDG uptake on images acquired during treatment limits
the use of automatic segmentation methods [8]. Acute
inflammatory reactions, as reported in head and neck
cancer [36], may also hamper the analyses of PET im-
ages during treatment. Oesophagitis was present in 9
out of 46 (19%) patients, and 3 of 46 had a nasogastric
feeding tube.
In a previous analysis of the same group of patients
[27], smaller TVs at baseline (PET1) and at day 21
(PET2) were associated to higher probabilities of re-
sponse at 3 months, as already reported by otherinvestigators [25,37,38]. However, we failed to demon-
strate a prognostic value for Δ%SUVmax, Δ%SUVmean
or Δ%TV, showing similar evolution of these quantita-
tive parameters whatever the tumour response to treat-
ment. These indices are calculated over the whole
tumour and do not address spatial variations of response
to treatment within the tumour. In the present report,
we aimed at investigating intra-tumour heterogeneity in
FDG uptake as an early measure of response to treat-
ment, our results being in line with the encouraging
ones published in oesophageal (mixing SCC and adeno-
carcinomas), cervical and head and neck cancers [39,40].
Table 2 Univariate analysis according to outcome at 3 months
Endpoint at 3 months
CR (n = 29) Failure/death (n = 17) p
Clinical factors
Age 64.0 (59.6 to 68.3) 59.4 (53.9 to 64.9) 0.18
F/M 3/26 1/16 1.0
T2/T3/T4 2/27/0 4/8/5 0.001
1/2-site T 28/1 13/4 0.055
N0/N1 22/7 8/9 0.048
FDG-PET/CT parameters
SUVmax1 12.5 (10.8 to 14.2) 15.4 (10.9 to 20.0) 0.44
TV1 9.7 (7.2 to 13.1) 20.6 (13.2 to 32.2) 0.004
SUVmax2 7.1 (5.9 to 8.2) 8.6 (6.4 to 10.9) 0.23
TV2 4.8 (3.3 to 6.9) 11.1 (4.6 to 13.6) 0.009
Vg 3.1 (1.8 to 5.1) 5.8 (3.5 to 9.8) 0.056
Vr 5.6 (4.0 to 7.9) 9.8 (6.2 to 15.5) 0.047
Quantitative variables: mean (95% confidence limits).
Vera et al. EJNMMI Research 2014, 4:12 Page 6 of 9
http://www.ejnmmires.com/content/4/1/12In both analyses, the patients with CR (either at
3 months or at 1 year) were older than the ones who
died or whose tumour relapsed. These differences were
statistically significant at 3 months and 1 year in the
present analysis, varying from our original report [27],
where age was a predictor of outcome only at 1 year and
not at 3 months, possibly as a consequence of the exclu-
sion of two patients and/or the introduction of new vari-
ables (Vg and Vr) in the logistic model.
Our aim was to characterise the variations in FDG up-
take at the voxel level. The parameters were extracted
from an image set combining the FDG-PET/CTs per-
formed before and during CRT. This procedure is similar
to the use of ictal and interictal perfusion single-photonTable 3 Univariate analysis according to outcome at 1 year
En
CR (n = 22)
Clinical factors






SUVmax1 10.9 (9.3 to 12.9)
TV1 9.0 (6.5 to 12.5)
SUVmax2 6.3 (5.2 to 7.6)
TV2 6.2 (3.7 to 10.2)
Vg 3.2 (2.1 to 4.7)
Vr 4.5 (3.1 to 6.6)
Quantitative variables: mean (95% confidence limits).emission computed tomography (SPECT) in the SISCOM
procedure [41]. Such an approach critically relies on regis-
tration accuracy. Our FDG-PET/CTs were co-registered
over the thorax region using a rigid method, then visually
inspected and, if necessary, re-registered with an affine
registration method. The repeatability of the method has
been previously validated, as well as the impact of misreg-
istration on the generation of green and red clusters [26].
The classification of the voxels according to the differ-
ences in uptake at PET1 and PET2 and their position as
regards the CT tumour volume were visually checked.
Some voxels obviously belonging to the heart or related to
oesophagitis had to be manually re-classified. Our previ-
ous analysis [27] failed to support FDG uptake ordpoint at 1 year
Failure/death (n = 24) p





13.7 (11.2 to 16.8) 0.08
17.8 (12.2 to 26.0) 0.007
7.5 (6.0 to 9.3) 0.22
7.0 (4.5 to 10.7) 0.69
5.3 (2.9 to 9.8) 0.33
10.2 (7.1 to 14.5) 0.002
Table 4 Multivariate analysis of outcome at 3 months and 1 year (logistic regression)
Endpoint Covariates Odds ratio (95% CI) p Correctly classified AUC ROC
3 months Age 0.94 (0.90 to 0.98) 0.001 76% 0.84
Ln(TV1) 2.93 (1.31 to 6.60) 0.009
Ln(1 + Vg) 2.23 (1.01 to 4.96) 0.047
1 year Age 0.95 (0.92 to 0.99) 0.006 78% 0.89
N+ 20.9 (2.24 to 195) 0.008
Ln(Vr) 3.08 (1.12 to 8.46) 0.03
Natural logarithm (Ln) transformations were used to obtain Gaussian distributions for quantitative variables. 95% CL, 95% confidence limits; AUC ROC, area under
receiver operating characteristics curve.
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dictive indices. In the present study, a predictive value of
Vr and Vg (including Ln(Vr) or Ln(1 +Vg)) was demon-
strated in multivariate analyses, suggesting that PET2
could be of clinical interest.
The main feature of the present parametric method pre-
sented here is the quantification of tumour response to
treatment at the voxel level, possibly more informative
than a single value (e.g. SUVmax) calculated over the
whole functional volume. Our method seems attractive
when monitoring tumour response on serial FDG-PET/
CT as oesophageal cancers are hardly visible on the CT
images. The present method could become a valuable tool
to quantify dissociated responses on multiple tumour
sites, e.g. primary tumour and metastatic nodes, provided
that all the regions of interest are selected. Multivariate
analyses showed that the parametric method added some
predictive value to more conventional variables. The asso-
ciation between larger green volumes (i.e. decreased up-
take between PET1 and PET2) and worse outcome at
3 months appears to be counter-intuitive. Our data sug-
gest that large initial tumour volumes are the most likely
(1) to shrink during treatment (explaining the large abso-
lute green volumes) and (2) to shrink only partially, so
persistent activity is still visible on PET2. For example, if a
50-cm3 functional volume at PET1 decreased to 30 cm
3 at
PET2 (i.e. a major response), a large green volume
(20 cm3) would be anyway associated to a bad outcome
related to the large initial volume. In contrast, a small
green volume (e.g. 2 cm3) would be measured on a 5-cm3
initial functional volume with the response of similar
amplitude, i.e. a 3-cm3 residual volume at PET2, also asso-
ciated to treatment failure despite a relatively small initial
volume. Statistically speaking, our limited number of pa-
tients precluded us to test for interaction between initial
and green volumes. The omission of the green volume
from the multivariate analyses did not alter the proportion
of correctly classified patients (76% (3 months) and 78%
(1 year)), but slightly decreased the area under the ROC
curve (from 0.84 to 0.79).
A limitation of the present study is the relatively small
number of evaluable patients. The planned sample sizewas not reached due to accrual slower than anticipated
[27]. We could anyway demonstrate that 46 patients
with oesophageal SCC could be prospectively recruited
in a multicenter setting, all investigators abiding to strict
acquisition procedures and analysed together using an
innovative approach. The clinical value of FDG-PET/CT
during radiotherapy deserves further validation, possibly
using the method presented here.
Conclusion
This prospective, multicentre study performed in pa-
tients with squamous cell oesophageal cancer evaluated
a parametric method to monitor heterogeneous tumour
response patterns on serial FDG-PET/CT images ac-
quired during radiotherapy. We demonstrate its feasibil-
ity and ability to characterise early metabolic changes
and suggest that it provides added prognostic informa-
tion to conventional variables such as SUVmax and TV.
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